Microvolt T-Wave Alternans Testing To Be Covered by CIGNA HealthCare.

BEDFORD, Mass. -- Cambridge Heart, Inc. (OTCBB: CAMH) today announced that CIGNA HealthCare has revised its Coverage Position on Microvolt T Wave Alternans testing, agreeing to make it a covered benefit for its beneficiaries. The Coverage Position now states:

"CIGNA HealthCare covers microvolt T-wave alternans (MTWA) testing as a method to identify risk of ventricular arrhythmias and sudden cardiac death for patients who meet criteria for implantable cardioverter defibrillator placement."

CIGNA HealthCare is one of the nations leading providers of healthcare benefits covering over 12 million people across the country.

"We are very pleased that after reviewing all of the published literature on Cambridge Heart's system, including last month's publication in JACC by Dr. Theodore Chow, CIGNA has recognized the benefit that MTWA can provide to their beneficiaries," said David Chazanovitz, President and CEO of Cambridge Heart, Inc. "The utilization of our diagnostic test in patients eligible for implantable defibrillator therapy is becoming more and more important as physicians work to provide the most appropriate individualized care for their patients."

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or, who are at risk of, life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.